The study showed that users of cholinesterase inhibitors like Aricept, Exelon and Reminyl are more likely to experience slower heart rates and a higher rate of fainting.
+Alzheimer's Reading Room
|Subscribe to the Alzheimer's Reading Room|
This study published in the journal Archives of Internal Medicine caught my attention.
In the case of my mother, her heart rate did slow after she was put on the combination of Aricept and Namenda.
When I first noticed this (her heart rate came up when I was taking her blood pressure) it disturbed me, and I decided to discuss the issue with her personal care physician. He told me to continue to monitor her heart rate, and let him know if it dropped below 55.
My mother was not fainting. However, she did tell me repeatedly each day that she felt like she was going to faint, or she said, I'm dizzy. This is probably the side effect of one or more of her medications.
There was a little blue sticker on the side of the Amlodipine medication bottle warning me that dizziness was a potential side effect. This was helpful. Helpful when they remember to put the sticker on the bottle, they don't always do it.
In order to understand how medications work, you should read the disclosure statement that comes with the medication. This way you will learn the side effects and risks.
I know many Alzheimer's caregivers that experience problems with fainting, and as a result, they live in a state of angst and worry.
Fainting leads to frequent 9-1-1 calls, and also brings risk such as the dreaded broken hip. Fainting is certainly a cause for concern.
Does your loved one living with dementia mention dizziness?
Most of us would probably conclude that fainting is caused by Alzheimer's, and not a problem brought on by the side effects of a medication(s). This new study highlights the potential side effects of cholinesterase inhibitors.
The scientists are not suggesting that Alzheimer's patients stop taking cholinesterase inhibitors, and neither am I.
However, if you are experiencing these problems you might want to discuss these issues with your personal care physician or a specialist.
- What is the Difference Between Alzheimer’s and Dementia
- Test Your Memory for Alzheimer's (5 Best Memory Tests)
- First Sign of Alzheimer's Short Term Memory Loss
- What is Alzheimer's Disease?
- Is Alzheimer's World an Irrational Place?
- Communicating in Alzheimer's World
- The Seven Stages of Alzheimer's
Dementia drugs may put some patients at risk, Queen’s study shows
Cholinesterase inhibitors (Aricept, Exelon and Reminyl) are often prescribed for people with Alzheimer's disease and related dementias because they increase the level of a chemical in the brain that seems to help memory. Although such drugs are known to provoke slower heart rates and fainting episodes, the magnitude of these risks has not been clear until now.
"This is very troubling, because the drugs are marketed as helping to preserve memory and improve function," says Dr. Gill, who is an Ontario Ministry of Health and Long-term Care Career Scientist, working at Providence Care's St. Mary's of the Lake Hospital in Kingston. "But for a subset of people, the effect appears to be the exact opposite."
In a large study using province-wide data, Dr. Gill and his colleagues discovered that people who used cholinesterase inhibitors were hospitalized for fainting almost twice as often as people with dementia who did not receive these drugs. Experiencing a slowed heart-rate was 69 per cent more common amongst cholinesterase inhibitor users. In addition, people taking the dementia drugs had a 49 per cent increased chance of having permanent pacemakers implanted and an 18 per cent increased risk of hip fractures.
Unfortunately, Dr. Gill continues, this class of drugs is one of the few effective dementia treatments available today. Acknowledging that these drugs do have an important role in the management of dementia, he suggests that people who are already at a higher risk (for example, those who have had previous episodes of fainting or slowed heart rate) may want to ask their doctors to reassess the value of taking the drugs.
Slowing of the heart rate from cholinesterase inhibitors, if significant, may cause a person to faint and suffer fall-related injuries such as a broken hip - often debilitating and sometimes fatal for seniors. However, many physicians aren't aware of the connection between these problems and the dementia drugs, Dr. Gill notes.
If the association with dementia drugs is not identified, people who faint may be prescribed a permanent pacemaker: an invasive procedure that can involve serious complications for seniors. Both the injuries incurred from falling and the risks from pacemaker implants are "downstream consequences" of not recognizing this drug-induced phenomenon.
"This study does not suggest that dementia patients shouldn't take these drugs," says Dr. Gill. "What's critical is that patients, caregivers and physicians be aware of the potential side effects, and weigh these risks carefully against the potential for beneficial effects."
The findings are published in the journal, Archives of Internal Medicine.
Scientists from the Institute for Clinical Evaluative Sciences, the University of Toronto and Harvard University are also on the research team.
The study uses data housed at the Institute for Clinical Evaluative Sciences (ICES). Ontario's first satellite unit of ICES was established at Queen's in 2007 to provide university researchers with electronic access to Ontario health datasets and population registries by secured and encrypted lines. Areas of focus at Queen's include cancer, pharmacological studies and dementia.
Original content the Alzheimer's Reading Room